AI Accelerates Biologic Drug Design and Development

Artificial intelligence is rapidly transforming the pharmaceutical research and development sector, particularly in the design of biologic medicines. The traditional process of developing new drugs is notoriously expensive, time-consuming, and prone to failure, with many potential candidates never reaching patients. Biologic medicines, which are derived from engineered proteins, present even greater complexity due to the vast number of possible molecular combinations that need to be evaluated for efficacy, stability, and manufacturability.

Companies like AstraZeneca are integrating AI into their core R&D infrastructure to address these challenges. Puja Sapra, senior vice president and head of R&D biologics engineering and oncology targeted discovery at AstraZeneca, stated that "Everything we do, whether it’s design, make, test, or analyze, is now computationally enhanced." This computational enhancement is leading to shorter cycle times, increased productivity, and greater innovation in drug discovery.

AstraZeneca employs a "build-measure-learn" loop where AI algorithms generate or prioritize candidate molecules by predicting their likelihood of success. This allows scientists to concentrate laboratory resources on the most promising candidates, creating a more efficient feedback cycle. This approach reduces the number of dead ends, enables faster iteration, and opens possibilities for targeting diseases previously considered untreatable.

The sheer scale of potential molecular combinations in biologic drug design far surpasses human capacity for systematic exploration. AI's ability to narrow down and refine these options for testing has become a critical focus for the industry. By leveraging AI, researchers can navigate complex drug design problems more effectively, accelerating the timeline from initial concept to potential therapeutic.